Debord J, Voultoury J C, Lachatre G, Favereau J P, Gay R
Service de Pharmacologie et Toxicologie, C.H.R.U. Dupuytren, Limoges, France.
Int J Biomed Comput. 1994 Jun;36(1-2):135-7. doi: 10.1016/0020-7101(94)90105-8.
The pharmacokinetics of amikacin have been studied in 40 intensive care unit (ICU) patients using a two-compartment model and the Bayesian estimation method implemented in the USC PC-PACK program of Jelliffe et al. The volume of the central compartment was significantly higher in these patients (0.36 l.kg-1) than in the reference population (0.20 l.kg-1). A method has been designed to compute dosage regimens in order to maintain a constant steady-state average plasma concentration of 8 mg.l-1 for repeated i.v. infusions. The regimen calculated for the 'average' ICU patient varies between 11 mg.kg-1 three times per day for the patient with normal renal function and 6 mg.kg-1 every 2 days for the anuric patient. This regimen is intended to begin amikacin therapy in an ICU patient, while the population pharmacokinetic parameters would allow the individualization of the regimen by means of the Bayesian method.
使用两室模型和杰利夫等人的南加州大学PC - PACK程序中实施的贝叶斯估计方法，对40名重症监护病房（ICU）患者的阿米卡星药代动力学进行了研究。这些患者中央室的容积（0.36 l·kg-1）显著高于参考人群（0.20 l·kg-1）。已设计出一种计算给药方案的方法，以便在重复静脉输注时维持8 mg·l-1的恒定稳态平均血浆浓度。为“普通”ICU患者计算的给药方案因患者而异，肾功能正常的患者为每日3次，每次11 mg·kg-1，无尿患者为每2天6 mg·kg-1。该方案旨在开始对ICU患者进行阿米卡星治疗，而群体药代动力学参数将允许通过贝叶斯方法对给药方案进行个体化调整。
